Developer docs
API playgroundTry for free, no card

Search company profiles

Mirxes

Full company profile

uuid0000ao4

Namestring
Mirxes
Legal namestring
Mirxes Holding Pte. Ltd.
Websiteurl
mirxes.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Mirxes is a Singapore-headquartered RNA diagnostics company founded in 2014 and listed on the Hong Kong Stock Exchange (ticker hkg:2629), specialising in blood-based microRNA tests for early cancer detection. Its core technology is the proprietary ID3EAL RT-qPCR platform, which underpins GASTROClear — the world's first molecular blood test for gastric cancer screening, detecting 12 miRNA biomarkers with 87% sensitivity — and LUNGClear for early-stage lung cancer detection. The portfolio extends to NGS-based cancer treatment selection panels (APEX Tissue with 58 genes; COMPASS Tissue with 1,021 genes), precision multiomics research services (spatial transcriptomics, single-cell sequencing, WGS/WES, RNA-Seq, methylation), the Cryomics biobanking service, and Fortitude RT-PCR infectious-disease kits.

Mirxes operates a hybrid business model spanning clinical diagnostic services through its wholly owned M Diagnostics laboratory, sales of diagnostic test kits and reagents to hospitals and laboratories, research and bioinformatics services to pharmaceutical and academic clients, and biobanking managed services. Commercialisation follows a regulatory-led go-to-market: GASTROClear has secured FDA Breakthrough Device Designation, CE Mark, Singapore HSA Class C IVD approval, and China NMPA approval, and is sold through a network of over 200 clinics and hospitals in Singapore — anchored by NUH, Tan Tock Seng, SGH, NCCS, and Raffles Medical — alongside distribution in six Asia Pacific markets and a recently opened China commercial operation. Operations span Singapore (HQ, manufacturing, R&D, and clinical lab), Hangzhou, Tokyo, and Cambridge, MA, with an emerging agentic AI clinical decision-support capability built on Oracle Cloud Infrastructure.

Mirxes is led by Co-founder and CEO Dr. Zhou Lihan, with Co-founder Prof. Too Heng-Phon as Chief Scientific Advisor and Non-Executive Chairman; the management bench was expanded with appointments including a Chief Investment Officer and Chief Financial Officer ahead of the May 2025 IPO that raised HK$1.09 billion and made the company Southeast Asia's first biotech unicorn.

Short descriptiontext

Mirxes is a Singapore-based RNA diagnostics company that develops proprietary blood-based miRNA test kits — including GASTROClear and LUNGClear — for early cancer detection, serving hospitals, clinics, oncology providers, and research institutions across Asia Pacific.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular cancer diagnostics, miRNA blood tests, cancer early detection, clinical genomic sequencing, precision oncology diagnostics
Industry6 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Cancer Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical Diagnostic Services
TypeProfessional Services
Description

Mirxes provides clinical testing services through its M Diagnostics laboratory, offering molecular diagnostic tests for cancer early detection and treatment selection. Services include GASTROClear testing, NGS-based tumor profiling, and other clinical sequencing services.

mirxes.com
2Diagnostic Test Kits
TypeOne Time License
Description

Sale of diagnostic test kits including GASTROClear, LUNGClear, Fortitude Kit 2.1 (RT-PCR test for SARS-CoV-2), and RNA extraction kits. Products are sold to hospitals, clinics, and laboratories.

mirxes.com
3Research and Precision Multiomics Services
TypeProfessional Services
Description

Genomics and bioinformatics services including Stereo-seq spatial transcriptomics, single-cell sequencing, WGS, WES, RNA-Seq, and methylation sequencing for research and discovery purposes.

mirxes.com
4Biobanking Services
TypeManaged Services
Description

Cryomics biobanking solutions for secure storage of biological samples and consultancy services.

businesstimes.com.sg
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Public sector patients may benefit from more than 50% cost reduction compared to sending samples overseas for APEX NGS testing
ModelOtherBilling cadencePay-as-you-go
Notes

The APEX cancer treatment selection test offers significant cost reduction for public sector patients compared to overseas testing, with results available in 8 working days compared to 3 weeks previously.

mirxes.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1GASTROClear
Description

World's first molecular blood test for early detection of gastric cancer, detecting 12 gastric cancer-associated miRNA biomarkers.

mirxes.com
+7 more records
Core offering1 text field

Mirxes develops and commercializes proprietary RNA-based diagnostic test kits and clinical services for early cancer detection, built on its miRNA biomarker technology platform. Its flagship product, GASTROClear, is the world's first molecular blood test for early detection of gastric cancer using 12 miRNA biomarkers, complemented by LUNGClear for lung cancer, NGS-based APEX Tissue and COMPASS Tissue panels for cancer treatment selection, and Fortitude infectious disease RT-PCR kits. The company also operates clinical diagnostic services through its M Diagnostics laboratory and offers Precision Multiomics research services and Cryomics biobanking.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 87% sensitivity for early-stage gastric cancer detection (Stage I: 87.5%, Stage II: 89.5%)
+4 more records
Product overview1 text field

Mirxes offers a portfolio of RNA-based diagnostic products and services centered on its proprietary miRNA technology platform. The core offerings include GASTROClear (world's first molecular blood test for gastric cancer detection) and LUNGClear (lung cancer blood test), both leveraging the ID3EAL Suite RT-qPCR technology. For cancer treatment selection, the company provides APEX Tissue (58-gene NGS panel) and COMPASS Tissue (1,021-gene NGS panel). The portfolio extends to infectious disease testing (Fortitude COVID/Flu tests), precision multiomics research services (spatial transcriptomics, single-cell sequencing, WGS/WES), and biobanking through Cryomics. The company operates clinical studies including CADENCE (multi-cancer early detection for 9 cancer types) and ELEGANCE (liver cancer detection), with an agentic AI assistant for clinical decision support. The platform spans cancer screening, treatment selection, and research solutions.

Product and service10 records
1GASTROClear
CategoryCancer Screening Diagnostics
Description

The world's first molecular blood test for early detection of gastric (stomach) cancer, detecting 12 gastric cancer-associated miRNA biomarkers using RT-qPCR technology with 87% sensitivity. For adults aged 40+ at elevated risk (family history, H. pylori, chronic gastritis, dietary risk factors).

2LUNGClear
CategoryCancer Screening Diagnostics
Description

Minimally invasive blood test designed to identify lung cancer at an early stage, leveraging Mirxes' proprietary miRNA technology platform for early detection in high-risk individuals.

3APEX Tissue
CategoryCancer Treatment Selection
Description

Targeted 58-gene Next-Generation Sequencing (NGS) profiling test for cancer treatment selection. Identifies genetic alterations in tumors that may respond to specific targeted therapies, with results delivered in 8 working days at 50%+ cost reduction versus overseas testing.

4COMPASS Tissue
CategoryCancer Treatment Selection
Description

Comprehensive 1021-gene profiling test using NGS for personalized treatment decisions across multiple solid tumor types, enabling broad genomic profiling for oncology therapy selection.

5ID3EAL Suite
CategoryTechnology Platform
Description

Proprietary RT-qPCR technology platform enabling class-leading, highly sensitive detection of microRNAs, forming the foundation for Mirxes' diagnostic assays and offered as a standalone technology platform.

6Fortitude Kit 2.1
CategoryInfectious Disease Diagnostics
Description

Multiplex RT-PCR test for SARS-CoV-2 detection, a proven testing solution developed during the COVID-19 pandemic.

7Fortitude SARS-CoV-2 & FluA/B Test
CategoryInfectious Disease Diagnostics
Description

RT-PCR kit for simultaneous detection of SARS-CoV-2 and Influenza A/B viruses, sold to clinical laboratories and healthcare providers.

8Precision Multiomics
CategoryResearch Services
Description

Genomics and bioinformatics services including Stereo-seq spatial transcriptomics, single-cell whole genome sequencing, WGS, WES, RNA-Seq, methylation sequencing, and shotgun metagenomic sequencing for research and discovery.

9Cryomics
CategoryBiobanking Services
Description

Biobanking solutions offering secure storage and consultancy services for biological samples, operated as a partnering discovery service by Mirxes.

10RNA Extraction Kits & Instruments
CategoryMolecular Reagents and Instruments
Description

RNA swab and saliva sample collection kits along with molecular and COVID-19 RNA extraction kits and instruments for use by clinical and research laboratories.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-22
Description

Mirxes is piloting an agentic AI clinical assistant built using Oracle AI Database and Oracle Cloud Infrastructure. The system uses semantic search and retrieval-augmented generation to deliver near real-time responses to clinician queries.

2Singapore Gastric Cancer Consortium (SGCC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Multi-institutional consortium including leading Singapore healthcare institutions for gastric cancer research, early detection development, and clinical validation of GASTROClear.

mirxes.com
3China National Medical Products Administration (NMPA)
Strategic tierCoreTypeOthersAnnounced on2025-10-09
Description

Regulatory approval body that granted approval for GASTROClear commercialization in China, enabling market access in one of the world's largest gastric cancer markets.

einpresswire.com
Strategic tierExploratoryTypeStrategic or Co-development PartnerAnnounced on2024-05-24
Description

Mirxes and PULSE TCM launched the 'East Meets West' Community Health Screening Pilot, combining Western precision diagnostic technology (GASTROClear) with Eastern TCM preventive medicine approaches for holistic health screening.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-13
Description

NUH and Mirxes established NUH DMOC@Biopolis, one of Singapore's first public-private partnership centers for specialty molecular testing. The center integrates NUH's Diagnostic Molecular Oncology Centre (DMOC) with Mirxes' clinical laboratory, combining clinical expertise with cutting-edge molecular testing infrastructure.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-10
Description

A*STAR spinoff with research collaboration through Bioprocessing Technology Institute (BTI), Diagnostics Development Hub (DxD Hub), and ecosystem partners. GASTROClear was developed through a seven-year public-private partnership with A*STAR institutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-01
Description

Lead institution for ELEGANCE study on early detection of hepatocellular carcinoma (HCC). Multi-center collaboration involving leading healthcare institutions for liver cancer detection using miRNA biomarkers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-01
Description

Research collaboration with NUS Yong Loo Lin School of Medicine, including the Singapore Gastric Cancer Consortium (SGCC), NUS Centre for Cancer Research (N2CR), and clinical studies at NUH.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-01
Description

International clinical collaboration for GASTROClear validation, conducting large prospective clinical trials involving over 9,000 patients in China alongside seven academic clinical institutions.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1GRAIL
TypeDirect peer
Description

US-based multi-cancer early detection company (an Illumina subsidiary) commercializing the Galleri blood test that screens for multiple cancers from a single draw. Closest direct competitor to Mirxes' CADENCE multi-cancer screening platform in terms of clinical ambition and regulatory pathway.

TypeEmerging player
Description

US-based cancer genomics company developing ultra-sensitive NGS tests for tumor profiling and neoantigen detection. Comparable peer in next-generation tumor profiling approaches, though operating at earlier commercial scale than Foundation Medicine.

TypeDirect peer
Description

US-based precision oncology company offering blood-based liquid biopsy tests for tumor profiling and minimal residual disease. Mirxes' APEX and COMPASS NGS tissue panels compete in adjacent oncology molecular diagnostic indications, with Mirxes' miRNA-first approach offering a differentiated biomarker strategy.

TypeBroad incumbent
Description

US-based NGS tumor profiling leader (Roche subsidiary) offering FoundationOne CDx and FoundationOne Liquid CDx. Broad incumbent in the comprehensive genomic profiling market that Mirxes' COMPASS Tissue panel competes against, especially in oncology treatment selection.

5Genetron Health
TypeDirect peer
Description

China-based precision oncology company offering NGS-based tumor profiling and early screening services. Direct peer in the Chinese oncology diagnostics market, particularly for NGS tumor profiling panels similar to APEX/COMPASS.

TypeDirect peer
Description

US-based developer of non-invasive cancer screening and molecular diagnostic tests, including the Cologuard colorectal screening test and an emerging multi-cancer early detection program. Mirxes competes most directly via GASTROClear and CADENCE for non-invasive, blood-based cancer screening positioning.

TypeDirect peer
Description

China-based NGS-based cancer therapy selection company. Direct peer in the Chinese oncology molecular diagnostics market where Mirxes is now entering via NMPA-approved GASTROClear and is positioned to introduce APEX/COMPASS tumor profiling tests.

8New Horizon Health (诺辉健康)
TypeDirect peer
Description

China-based early cancer screening company (HKEX-listed) commercializing non-invasive screening tests including ColoClear for colorectal cancer. Most direct Asia peer in blood/stool-based early cancer detection consumer and clinical markets.

TypeBroad incumbent
Description

US-based cell-free DNA testing company with Signatera MRD test and growing oncology franchise. Comparable peer in liquid biopsy oncology applications, with broader reproductive testing portfolio but overlapping oncology molecular diagnostic capabilities.

TypeDirect peer
Description

China-headquartered genomics services provider offering WGS, WES, RNA-Seq, and single-cell sequencing for research customers. Direct peer in Mirxes' Precision Multiomics service line (Stereo-seq, scWGS, WGS/WES, methylation sequencing), competing for the same APAC research and pharma customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mirxes

Molecular Cancer Diagnosticsmirxes.com

Mirxes is a Singapore-based RNA diagnostics company that develops proprietary blood-based miRNA test kits — including GASTROClear and LUNGClear — for early cancer detection, serving hospitals, clinics, oncology providers, and research institutions across Asia Pacific.

What Mirxes does

Mirxes is a Singapore-headquartered RNA diagnostics company founded in 2014 and listed on the Hong Kong Stock Exchange (ticker hkg:2629), specialising in blood-based microRNA tests for early cancer detection. Its core technology is the proprietary ID3EAL RT-qPCR platform, which underpins GASTROClear — the world's first molecular blood test for gastric cancer screening, detecting 12 miRNA biomarkers with 87% sensitivity — and LUNGClear for early-stage lung cancer detection. The portfolio extends to NGS-based cancer treatment selection panels (APEX Tissue with 58 genes; COMPASS Tissue with 1,021 genes), precision multiomics research services (spatial transcriptomics, single-cell sequencing, WGS/WES, RNA-Seq, methylation), the Cryomics biobanking service, and Fortitude RT-PCR infectious-disease kits.

Mirxes operates a hybrid business model spanning clinical diagnostic services through its wholly owned M Diagnostics laboratory, sales of diagnostic test kits and reagents to hospitals and laboratories, research and bioinformatics services to pharmaceutical and academic clients, and biobanking managed services. Commercialisation follows a regulatory-led go-to-market: GASTROClear has secured FDA Breakthrough Device Designation, CE Mark, Singapore HSA Class C IVD approval, and China NMPA approval, and is sold through a network of over 200 clinics and hospitals in Singapore — anchored by NUH, Tan Tock Seng, SGH, NCCS, and Raffles Medical — alongside distribution in six Asia Pacific markets and a recently opened China commercial operation. Operations span Singapore (HQ, manufacturing, R&D, and clinical lab), Hangzhou, Tokyo, and Cambridge, MA, with an emerging agentic AI clinical decision-support capability built on Oracle Cloud Infrastructure.

Mirxes is led by Co-founder and CEO Dr. Zhou Lihan, with Co-founder Prof. Too Heng-Phon as Chief Scientific Advisor and Non-Executive Chairman; the management bench was expanded with appointments including a Chief Investment Officer and Chief Financial Officer ahead of the May 2025 IPO that raised HK$1.09 billion and made the company Southeast Asia's first biotech unicorn.

Mirxes firmographics

Firmographics
Name
Mirxes
Legal name
Mirxes Holding Pte. Ltd.
Website
https://mirxes.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Mirxes is a Singapore-based RNA diagnostics company that develops proprietary blood-based miRNA test kits — including GASTROClear and LUNGClear — for early cancer detection, serving hospitals, clinics, oncology providers, and research institutions across Asia Pacific.
Ownership category
akta.pro rank

Mirxes industry classification

Industry
Product category
Molecular Cancer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Molecular cancer diagnostics
  • MiRNA blood tests
  • Cancer early detection
  • Clinical genomic sequencing
  • Precision oncology diagnostics

Where Mirxes is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices8 records

Markets served

Mirxes business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Diagnostic Services: Mirxes provides clinical testing services through its M Diagnostics laboratory, offering molecular diagnostic tests for cancer early detection and treatment selection. Services include GASTROClear testing, NGS-based tumor profiling, and other clinical sequencing services.
  2. Diagnostic Test Kits: Sale of diagnostic test kits including GASTROClear, LUNGClear, Fortitude Kit 2.1 (RT-PCR test for SARS-CoV-2), and RNA extraction kits. Products are sold to hospitals, clinics, and laboratories.
  3. Research and Precision Multiomics Services: Genomics and bioinformatics services including Stereo-seq spatial transcriptomics, single-cell sequencing, WGS, WES, RNA-Seq, and methylation sequencing for research and discovery purposes.
  4. Biobanking Services: Cryomics biobanking solutions for secure storage of biological samples and consultancy services.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPublic sector patients may benefit from more than 50% cost reduction compared to sending samples overseas for APEX NGS testing

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Mirxes product offering

Product offering

Core offering

Mirxes develops and commercializes proprietary RNA-based diagnostic test kits and clinical services for early cancer detection, built on its miRNA biomarker technology platform. Its flagship product, GASTROClear, is the world's first molecular blood test for early detection of gastric cancer using 12 miRNA biomarkers, complemented by LUNGClear for lung cancer, NGS-based APEX Tissue and COMPASS Tissue panels for cancer treatment selection, and Fortitude infectious disease RT-PCR kits. The company also operates clinical diagnostic services through its M Diagnostics laboratory and offers Precision Multiomics research services and Cryomics biobanking.

Product overview

Mirxes offers a portfolio of RNA-based diagnostic products and services centered on its proprietary miRNA technology platform. The core offerings include GASTROClear (world's first molecular blood test for gastric cancer detection) and LUNGClear (lung cancer blood test), both leveraging the ID3EAL Suite RT-qPCR technology. For cancer treatment selection, the company provides APEX Tissue (58-gene NGS panel) and COMPASS Tissue (1,021-gene NGS panel). The portfolio extends to infectious disease testing (Fortitude COVID/Flu tests), precision multiomics research services (spatial transcriptomics, single-cell sequencing, WGS/WES), and biobanking through Cryomics. The company operates clinical studies including CADENCE (multi-cancer early detection for 9 cancer types) and ELEGANCE (liver cancer detection), with an agentic AI assistant for clinical decision support. The platform spans cancer screening, treatment selection, and research solutions.

Differentiator

Problem solved

Functional benefit

Brands

  • GASTROClear: World's first molecular blood test for early detection of gastric cancer, detecting 12 gastric cancer-associated miRNA biomarkers.
  • LUNGClear
  • APEX Tissue
  • COMPASS Tissue
  • Fortitude Kit 2.1
  • ID3EAL Suite
  • Cryomics
  • Project CADENCE

Products and services

  • GASTROClear The world's first molecular blood test for early detection of gastric (stomach) cancer, detecting 12 gastric cancer-associated miRNA biomarkers using RT-qPCR technology with 87% sensitivity. For adults aged 40+ at elevated risk (family history, H. pylori, chronic gastritis, dietary risk factors).
  • LUNGClear Minimally invasive blood test designed to identify lung cancer at an early stage, leveraging Mirxes' proprietary miRNA technology platform for early detection in high-risk individuals.
  • APEX Tissue Targeted 58-gene Next-Generation Sequencing (NGS) profiling test for cancer treatment selection. Identifies genetic alterations in tumors that may respond to specific targeted therapies, with results delivered in 8 working days at 50%+ cost reduction versus overseas testing.
  • COMPASS Tissue Comprehensive 1021-gene profiling test using NGS for personalized treatment decisions across multiple solid tumor types, enabling broad genomic profiling for oncology therapy selection.
  • ID3EAL Suite Proprietary RT-qPCR technology platform enabling class-leading, highly sensitive detection of microRNAs, forming the foundation for Mirxes' diagnostic assays and offered as a standalone technology platform.
  • Fortitude Kit 2.1 Multiplex RT-PCR test for SARS-CoV-2 detection, a proven testing solution developed during the COVID-19 pandemic.
  • Fortitude SARS-CoV-2 & FluA/B Test RT-PCR kit for simultaneous detection of SARS-CoV-2 and Influenza A/B viruses, sold to clinical laboratories and healthcare providers.
  • Precision Multiomics Genomics and bioinformatics services including Stereo-seq spatial transcriptomics, single-cell whole genome sequencing, WGS, WES, RNA-Seq, methylation sequencing, and shotgun metagenomic sequencing for research and discovery.
  • Cryomics Biobanking solutions offering secure storage and consultancy services for biological samples, operated as a partnering discovery service by Mirxes.
  • RNA Extraction Kits & Instruments RNA swab and saliva sample collection kits along with molecular and COVID-19 RNA extraction kits and instruments for use by clinical and research laboratories.

Quantifiable outcome

  • 87% sensitivity for early-stage gastric cancer detection (Stage I: 87.5%, Stage II: 89.5%)
  • +4 more outcomes

Companies that use Mirxes

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Mirxes technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Mirxes partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and exploratory.

  • OraclecoreTechnology or Integration · 22 April 2026Mirxes is piloting an agentic AI clinical assistant built using Oracle AI Database and Oracle Cloud Infrastructure. The system uses semantic search and retrieval-augmented generation to deliver near real-time responses to clinician queries.
  • Singapore Gastric Cancer Consortium (SGCC)coreStrategic or Co-development Partner · 1 November 2025Multi-institutional consortium including leading Singapore healthcare institutions for gastric cancer research, early detection development, and clinical validation of GASTROClear.
  • China National Medical Products Administration (NMPA)coreOthers · 9 October 2025Regulatory approval body that granted approval for GASTROClear commercialization in China, enabling market access in one of the world's largest gastric cancer markets.
  • PULSE TCMexploratoryStrategic or Co-development Partner · 24 May 2024Mirxes and PULSE TCM launched the 'East Meets West' Community Health Screening Pilot, combining Western precision diagnostic technology (GASTROClear) with Eastern TCM preventive medicine approaches for holistic health screening.
  • National University Hospital (NUH)coreStrategic or Co-development Partner · 13 May 2024NUH and Mirxes established NUH DMOC@Biopolis, one of Singapore's first public-private partnership centers for specialty molecular testing. The center integrates NUH's Diagnostic Molecular Oncology Centre (DMOC) with Mirxes' clinical laboratory, combining clinical expertise with cutting-edge molecular testing infrastructure.
  • Agency for Science, Technology and Research (A*STAR)coreStrategic or Co-development Partner · 10 August 2023A*STAR spinoff with research collaboration through Bioprocessing Technology Institute (BTI), Diagnostics Development Hub (DxD Hub), and ecosystem partners. GASTROClear was developed through a seven-year public-private partnership with A*STAR institutions.
  • National Cancer Centre Singapore (NCCS)coreStrategic or Co-development Partner · 1 May 2021Lead institution for ELEGANCE study on early detection of hepatocellular carcinoma (HCC). Multi-center collaboration involving leading healthcare institutions for liver cancer detection using miRNA biomarkers.
  • National University of Singapore (NUS)coreStrategic or Co-development Partner · 1 May 2019Research collaboration with NUS Yong Loo Lin School of Medicine, including the Singapore Gastric Cancer Consortium (SGCC), NUS Centre for Cancer Research (N2CR), and clinical studies at NUH.
  • Yonsei Cancer Center (Korea)coreStrategic or Co-development Partner · 1 May 2019International clinical collaboration for GASTROClear validation, conducting large prospective clinical trials involving over 9,000 patients in China alongside seven academic clinical institutions.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Mirxes competitors and assessment

Company assessment

Direct peers

  • GRAIL: US-based multi-cancer early detection company (an Illumina subsidiary) commercializing the Galleri blood test that screens for multiple cancers from a single draw. Closest direct competitor to Mirxes' CADENCE multi-cancer screening platform in terms of clinical ambition and regulatory pathway.
  • Guardant Health: US-based precision oncology company offering blood-based liquid biopsy tests for tumor profiling and minimal residual disease. Mirxes' APEX and COMPASS NGS tissue panels compete in adjacent oncology molecular diagnostic indications, with Mirxes' miRNA-first approach offering a differentiated biomarker strategy.
  • Genetron Health: China-based precision oncology company offering NGS-based tumor profiling and early screening services. Direct peer in the Chinese oncology diagnostics market, particularly for NGS tumor profiling panels similar to APEX/COMPASS.
  • Exact Sciences: US-based developer of non-invasive cancer screening and molecular diagnostic tests, including the Cologuard colorectal screening test and an emerging multi-cancer early detection program. Mirxes competes most directly via GASTROClear and CADENCE for non-invasive, blood-based cancer screening positioning.
  • Burning Rock Biotech: China-based NGS-based cancer therapy selection company. Direct peer in the Chinese oncology molecular diagnostics market where Mirxes is now entering via NMPA-approved GASTROClear and is positioned to introduce APEX/COMPASS tumor profiling tests.
  • New Horizon Health (诺辉健康): China-based early cancer screening company (HKEX-listed) commercializing non-invasive screening tests including ColoClear for colorectal cancer. Most direct Asia peer in blood/stool-based early cancer detection consumer and clinical markets.
  • Novogene: China-headquartered genomics services provider offering WGS, WES, RNA-Seq, and single-cell sequencing for research customers. Direct peer in Mirxes' Precision Multiomics service line (Stereo-seq, scWGS, WGS/WES, methylation sequencing), competing for the same APAC research and pharma customers.

Emerging players

  • Personalis: US-based cancer genomics company developing ultra-sensitive NGS tests for tumor profiling and neoantigen detection. Comparable peer in next-generation tumor profiling approaches, though operating at earlier commercial scale than Foundation Medicine.

Broad incumbents

  • Foundation Medicine: US-based NGS tumor profiling leader (Roche subsidiary) offering FoundationOne CDx and FoundationOne Liquid CDx. Broad incumbent in the comprehensive genomic profiling market that Mirxes' COMPASS Tissue panel competes against, especially in oncology treatment selection.
  • Natera: US-based cell-free DNA testing company with Signatera MRD test and growing oncology franchise. Comparable peer in liquid biopsy oncology applications, with broader reproductive testing portfolio but overlapping oncology molecular diagnostic capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mirxes social profiles

Digital presence

Mirxes compliance and trust

Trust signal

Compliance7 records

Mirxes financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mirxes leadership team

Management profile

Number of profiles

Profiles6 records

Mirxes subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Mirxes funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mirxes M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mirxes

What does Mirxes do?

Mirxes develops and commercializes proprietary RNA-based diagnostic test kits and clinical services for early cancer detection, built on its miRNA biomarker technology platform. Its flagship product, GASTROClear, is the world's first molecular blood test for early detection of gastric cancer using 12 miRNA biomarkers, complemented by LUNGClear for lung cancer, NGS-based APEX Tissue and COMPASS Tissue panels for cancer treatment selection, and Fortitude infectious disease RT-PCR kits. The company also operates clinical diagnostic services through its M Diagnostics laboratory and offers Precision Multiomics research services and Cryomics biobanking.

Is Mirxes a public or private company?

Mirxes is a public company. It is classified as public and is currently operating.

When was Mirxes founded?

Mirxes was founded in 2014. It employs 101 to 250 people.

Where is Mirxes based?

Mirxes is headquartered in Singapore, Singapore, in the Asia region.

How does Mirxes make money?

Four revenue lines are on record. Clinical Diagnostic Services are the primary driver. The others are diagnostic Test Kits, research and Precision Multiomics Services and biobanking Services.

Who are Mirxes's main competitors?

Direct peers on record are GRAIL, Guardant Health, Genetron Health, Exact Sciences, Burning Rock Biotech, New Horizon Health (诺辉健康) and Novogene. Personalis is listed as an emerging player. Broad incumbents are Foundation Medicine and Natera.

Does Mirxes have an API?

No public API is recorded for Mirxes.

What industry is Mirxes in?

Mirxes's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireMirxes and NCCS launch blood test to spot liver cirrhosis risk earlierMirxes and NCCS launched CIRRHOClear, a blood-based microRNA test for liver cirrhosis risk, now commercially available in Singapore. The test shows 89% sensitivity and 95% specificity, targeting adults 40+ and higher-risk patients. It aims to enable earlier detection in primary care before irreversible damage.Business & FinancialMirxes And NCCS Launch Cirrhocleartm: A Breakthrough Blood Test For Early Liver Cirrhosis Risk StratificationMirxes and NCCS launched CIRRHOClearTM, a blood-based miRNA test for early liver cirrhosis risk stratification. The test, developed from the ELEGANCE study of 2,000 participants, showed 89% sensitivity and 95% specificity in clinical validation. It is offered as a Laboratory-Developed Test at M Diagnostics.The Straits TimesBiotech expansion with global standardsSingapore-based biotech firm Mirxes expanded its cancer-detection business to Thailand and Europe by treating global standards as infrastructure rather than mere compliance. The article highlights this strategy alongside cybersecurity firm i-Sprint, which is reportedly adopting a similar approach to drive its own expansion.ItnewsMirxes pilots agentic AI assistant to streamline clinical decision supportSingapore-based biotechnology company Mirxes is piloting an AI-driven clinical assistant to help healthcare professionals access and use complex diagnostic information more efficiently. The system, built using Oracle AI Database and Oracle Cloud Infrastructure, uses semantic search and retrieval-augmented generation to deliver near real-time responses to clinician queries. The assistant also incorporates agentic capabilities to automatically route product-related questions to relevant teams, aiming to reduce response times, ease clinician workload, and support more informed decision-making in clinical settings such as early cancer detection.The Business TimesUS$14.8 million in prepayments to vendors behind Mirxes’ missed 2025 results deadline; independent probe set upSingapore biotech company Mirxes disclosed that auditors flagged 14 transactions worth a combined US$14.8 million in prepayments to service providers and vendors as the reason for missing its mandatory annual results deadline. The company has set up an independent investigation committee comprising independent non-executive directors to review the transactions and has appointed Karas So and Alvarez & Marsal Disputes and Investigations as professional advisers. Trading in Mirxes shares on HKEX has been suspended since April 1, with US$9.5 million of prepayments already returned and US$5.3 million still outstanding.The Business TimesUS$14.8 million in prepayments to vendors reason behind Mirxes’ missed 2025 results deadline; independent probe set upSingapore biotech company Mirxes has disclosed that auditors flagged 14 transactions worth a combined US$14.8 million in prepayments to service providers and vendors, leading to its failure to meet the mandatory annual results deadline. The company has established an independent investigation committee, comprising independent non-executive directors Dr Judy Lam and Fang Xiao, which has appointed Karas So and Alvarez & Marsal Disputes and Investigations as independent professional advisers to review the transactions and compliance matters. Trading in Mirxes shares on the Hong Kong Stock Exchange has been suspended since April 1, with US$9.5 million in prepayments returned so far and US$5.3 million still outstanding.The Business TimesSingapore biotech Mirxes misses 2025 results deadline as auditors probe vendor paymentsMirxes, a Singapore biotech company specializing in miRNA-based cancer diagnostics, has missed its mandatory March 31, 2026 deadline to publish full-year 2025 results after auditors flagged concerns over a list of prepayments to service providers and vendors requiring further scrutiny. Trading in Mirxes shares was suspended from April 1, 2026, and will remain halted until the company publishes its delayed results. The board has declined to release unaudited management accounts in the interim, citing concerns about accuracy and potential shareholder confusion.Agency for Science, Technology and Research (A*STAR)Forget chasing the next Pfizer: Singapore’s biotech future lies in innovation, not giantsIndustry experts and government officials argue that Singapore should pivot from seeking a single domestic biotech giant to focusing on innovation, licensing deals, and strategic partnerships within its growing ecosystem. This strategy is supported by recent successes such as Mirxes becoming a unicorn, Nanyang Biologics pursuing a reverse merger, and Hummingbird Bioscience securing a $430 million licensing deal with Endeavor BioMedicines. Despite these wins, the sector faces persistent challenges including funding gaps for early and late-stage development, and a shortage of experienced commercial management talent.The Business TimesForget chasing the next Pfizer: Singapore’s biotech future lies in innovation, not giantsIndustry experts argue that Singapore should prioritize licensing deals and innovation hubs over pursuing home-grown biotech giants, citing the difficulty of competing with established global players. Despite challenges in funding and commercialization talent, local startups like Mirxes and Nanyang Biologics are achieving significant milestones through IPOs and partnerships. The sector continues to grow, supported by government investment and a strategic focus on R&D and clinical development.MirxesMirxes Announces US$40M Synthetic Royalty-Backed Financing from CBC Group’s R-Bridge to Accelerate Global GrowthMirxes announced a US$40 million synthetic royalty-backed financing from CBC Group's R-Bridge Healthcare Fund. The funding supports commercialization of its GASTROClear™ gastric cancer screening test, which showed 87.5% sensitivity for stage 1 cancers. Mirxes will expand into Asia-Pacific markets and accelerate clinical trials for other cancers.